Expertise in

conditions

Dr. Scott Schuetze

Oncology

University Of Michigan Medical Center

1500 E Medical Center Dr,

Ann Arbor, MI

Offers Telehealth

Expertise in

conditions

University Of Michigan Medical Center

1500 E Medical Center Dr,

Ann Arbor, MI

Overview

Scott Schuetze is an Oncologist in Ann Arbor, Michigan. Dr. Schuetze is highly rated in 30 conditions, according to our data. His top areas of expertise are Liposarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Myxoid Liposarcoma.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in MI

Hospital Affiliations

University Of Michigan Health System

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem BCBS

Blue Cross Blue Shield

Cambia Health Solutions

EPO
INSURANCE PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER COMMERCIAL
OTHER MEDICARE
PPO

CareSource

Cigna

Health Alliance Plan

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Humana

HMO
INDEMNITY
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

McLaren Health

Medicaid

OTHER MEDICAID
STATE MEDICAID

Meridian Choice

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D

Spectrum Priority Health

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER COMMERCIAL

UnitedHealthcare

University of Michigan Health

HMO
INSURANCE PLAN
MEDICARE MAPD

Upper Peninsula Health Plan

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE SNP
MEDICARE-MEDICAID PLAN

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 13 Less Insurance Carriers -

Locations

University of Michigan Medical Center
1500 E Medical Center Dr, Ann Arbor, MI 48109

Call: 734-647-8902

Other Locations

Office
1500 E Medical Center Dr Spc 5912, Ann Arbor, MI 48109

Call: 734-647-8904

Additional Areas of Focus

Dr. Schuetze has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST)

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Procedure, Drug

Study Drug: Rogaratinib

Study Phase: Phase 2

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma

Enrollment Status: Active_not_recruiting

Publish Date: February 12, 2026

Intervention Type: Other, Procedure, Drug, Biological

Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel

Study Phase: Phase 2

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2026

Intervention Type: Genetic

Study Phase: Phase 2

SARC038: A Phase 2 Study of Regorafenib in Combination With Nivolumab in Patients With Refractory or Recurrent Osteosarcoma

Enrollment Status: Active_not_recruiting

Publish Date: October 31, 2025

Intervention Type: Drug

Study Drugs: Regorafenib, Nivolumab

Study Phase: Phase 2

A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma